Table 3.
Treatment of patients infected with SARS-CoV-2 (N = 492).
| Treatment | Patients with AKI | Patients without AKI | p value |
|---|---|---|---|
| Diuretic | 11 (30.56%) | 18 (3.95%) | <0.001 |
| Quinolone | 34 (94.44%) | 389 (85.31%) | 0.13 |
| First- or second-generation cephalosporins | 0.00 | 22 (4.82%) | 0.18 |
| Penicillin | 8 (22.22%) | 88 (19.30%) | 0.67 |
| Antiviral | 34 (94.44%) | 393 (86.18%) | 0.16 |
| Glucocorticoid | 23 (63.89%) | 135 (29.61%) | <0.001 |
| NSAID | 8 (22.22%) | 108 (23.68%) | 0.84 |
| PPI | 23 (63.89%) | 212 (46.49%) | 0.04 |
| Traditional Chinese medicine | 2 (5.56%) | 43 (9.43%) | 0.44 |
Data are n/N (%), where N is the total number of patients with available data. p values comparing patients with AKI and without AKI are from chi-square or Mann–Whitney U test. SARS-CoV-2 = 2019 novel coronavirus; AKI = acute kidney injury; NSAID = nonsteroidal anti-inflammatory drugs; PPI = proton pump inhibitor.